

Beating cancer with existing CT scanners

Vinaver Medical Pitch Deck

2026



1 in 2

patients experience
increased toxicity


9 in 10

suffer **avoidable**
healthy tissue **damage**


**In cancer radiotherapy, CT is
more than an image - it's a map
that tells the beam where to stop.**

TissueXplorer® software enhances cancer treatment outcomes for 89% of radiotherapy patients*


Peer-reviewed



CT without Vinaver



 **Vinaver**




Superior diagnostics independent of MRI, timely therapy, and better care.

* Estimate based on achieved accuracy of 0.29% published in - <https://aapm.onlinelibrary.wiley.com/doi/10.1002/mp.70447>

We are driving adoption through fast implementation, low adoption barrier and better technology

Why adoption is happening?



Fast implementation

No workflow disruption,
patented integration



Low adoption barrier

Works with existing CT
systems and image viewers



Enhanced hospital ROI

More patients and better
results at scale

Validated in US
and EU markets

2 provisional
patents

Clear regulatory
approval path

Already in leading clinical sites

NEW YORK
PR***TON CENTER**


reference clinical center

Erasmus MC
University Medical Center Rotterdam



Clinical Centre of Serbia

Capturing ~\$80B CT market with 6% annual growth



Vendor-neutral integration grows install base and recurring licensing drives scalable revenue

Software License Fee(s)

Annual

\$30,000

inc. maintenance
per CT scanner

Lifetime

\$80,000

+15% maintenance
per CT scanner

LTV


\$130K

LTV CAC Ratio

4 : 1

Growth

3 year outlook



Experienced team supported by world class advisors



Stevan Vrbaški, PhD

Founder



Ljubomir Kurij

Product lead



Olivera Vujinović, PhD

R&D lead



Luka Vrbaški, BSc

Engineering lead



Jovan Lovrenski, MD, PhD

Clinical lead



Michael Maschke, Eng., MBA

Collaboration lead



Filip Ivancic, MIHMEP

Business advisor



Szabolcs Tóth, MBA

FDA advisor



- 60+ years of clinical work,
- 10+ regulatory approvals,
- 200+ approved patents,
- 70+ scientific publications,
- medtech exit

Raising \$3M to complete FDA clearance and launch in the U.S.



Funds will convert clinical traction into revenue

- ✓ FDA submission
- ✓ Team expansion
- ✓ Further clinical evidence
- ✓ Marketing and promotion
- ✓ Sales activities in USA

Centers in pipeline

NEW YORK
PROTON CENTER

HUNTSMAN

**Over \$20M pipeline
closable within 3 years.**

**Pre-seed stage
supported by:**

REPUBLIC OF SERBIA
INNOVATION
FUND



DSI
Business Angel
Network



startups

SCIENCE AND
TECHNOLOGY
PARK NOVI SAD



**Startup
Shower.**
winners

Scale SEE
winners